



ASX Release

COVID—19 (Coronavirus Pandemic) Market Update - Correction

Melbourne, Australia; 16 April 2020: Jayex Healthcare Limited (ASX: JHL) (**Jayex** or **Company**), advises of a correction to the announcement released on 9 April 2020 in the first paragraph, the percentage of approximate revenue growth should have read 20% not 25%.

An updated announcement with the corrected number is attached.

For and on behalf of the Board and for further information:

Chief Executive Officer
Nick Fernando
1300 330 611
n.fernando@jayex.com

Company Secretary
Melanie Leydin
+61 3 9692 7222

About Jayex Healthcare Limited - www.jayexhealthcare.com.au

Jayex Healthcare is a leading provider in the United Kingdom, Australia and New Zealand of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Jayex Connect* – the complete cloud-based Patient Engagement Platform;
- the *Enlighten* patient workflow platform;
- the *Appointuit* patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service; and
- the *BluePoint*[®] remote pharmacy prescription processing and dispensing terminal.

Jayex Healthcare Limited
(ACN 119 122 477)

Level 4, 100 Albert Road, South Melbourne, VIC, 3205



ASX Release

COVID—19 (Coronavirus Pandemic) Market Update

Melbourne, Australia; 9 April 2020: Jayex Healthcare Limited (ASX: JHL) (**Jayex** or **Company**), a leading UK and Australian e-health provider of integrated healthcare services delivery platforms, today released its market update due to the COVID-19 pandemic.

Preliminary results show strong Q1

Highlights:

- In Q1 (the Company's largest revenue earnings quarter) there was no adverse impact due to COVID-19.
- Q1 2020 preliminary results shows approximately 30% of the budgeted 2020 revenue target achieved.
- Q1 2020 preliminary results show a growth in revenue of approximately 20% YoY.
- Jayex has implemented cost saving initiatives and have streamlined costs by over \$200k. This includes cancelling all non-essential travel, marketing and other non-essential expenditure.
- All employees where appropriate are now working remotely. The Company is still providing a full and comprehensive service to our community of practices and hospitals under government guidelines.

The spread of COVID-19 continues to dominate the news, with major implications for public health and the health systems that we support in Australia, the U.K. and New Zealand. It is also causing economic disruption. However, JHL's strong preliminary Q1 results showing an approximate 20% growth in revenue over the same period last year, together with diligent cash flow and working capital management will stand the company in a position of strength in the coming months.

Our healthcare solutions play an important role in the day to day functioning of the healthcare systems that we operate in. This will continue and will become even more critical post COVID-19. We are also seeing some of our healthcare solutions playing a vital role during this pandemic and we are actively enhancing our solutions to support our customers even more so once we are over the critical stages of the pandemic. We have reason to believe that once we are over the worst stages of this pandemic, our solutions will be in greater demand across the markets that we operate in.

Nevertheless, in these challenging times we remain vigilant, we will monitor the situation continuously and we will react accordingly to the conditions that COVID-19 pose to us.

For and on behalf of the Board and for further information:

Chief Executive Officer
Nick Fernando
1300 330 611
n.fernando@jayex.com

Company Secretary
Melanie Leydin
+61 3 9692 7222

Jayex Healthcare Limited
(ACN 119 122 477)

Level 4, 100 Albert Road, South Melbourne, VIC, 3205



About Jayex Healthcare Limited - www.jayexhealthcare.com.au

Jayex Healthcare is a leading provider in the United Kingdom, Australia and New Zealand of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Jayex Connect* – the complete cloud-based Patient Engagement Platform;
- the *Enlighten* patient workflow platform;
- the *Appointuit* patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service; and
- the *BluePoint*® remote pharmacy prescription processing and dispensing terminal.